DeepLife

🌸 Marking Breast Cancer Awareness Day with New Insights into Oncology Research 🌟 In recognition of Breast Cancer Awareness Day, we are proud to highlight #DeepLife’s commitment to advancing cancer research through cutting-edge, data-driven approaches. 🔬 Our extensive #OmicStore offers researchers access to 709 unique datasets and over 49,052 experiments using single-cell technologies from both human and mouse models. These datasets are revolutionizing breast cancer research, providing critical insights into tumor progression, metastasis, and treatment resistance at the molecular level. What makes this even more impactful is the ability to combine DeepLife’s datasets with proprietary data from biotech and pharma companies. By integrating our meticulously curated data with in-house resources, researchers can better contextualize findings in preclinical and Phase 1/2 clinical studies, helping bridge the gap between experimental research and real-world applications in breast cancer treatment. 🧬 Our advanced #CellBlueprint interactome also supports drug repurposing and combination therapy studies, revealing new strategies to identify treatment targets. By understanding how different therapies interact at the cellular level, we’re accelerating the development of more personalized and effective breast cancer treatments. Interested in trying #CellBlueprint with a free trial? (https://lnkd.in/d4QxWx3S) ✨ Be Part of the Solution: Contact partnerships@deeplife.co to explore how our datasets can enhance your breast cancer research. Together, we can push the boundaries of what’s possible and bring hope to those affected by breast cancer. #BreastCancerAwareness #DeepLife #OmicStore #CellBlueprint #OncologyResearch #LifeSciences #PreclinicalResearch #ClinicalTrials #Bioinformatics #EliLilly #Roche #Merck #Novartis #JNJ #GSK #Sanofi #BristolMyersSquibb #AstraZeneca #Pfizer

DeepLife raises US$10m in Series A financing Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens en France Innovation Santé with participation from Beiersdorf Venture Capital, Groupe Prunay, and existing investors. Jonathan Baptista Jean-Baptiste MORLOT Read more: https://lnkd.in/ewt9vtMP

DeepLife raises US$10m in Series A financing Generative AI specialist DeepLife SAS has raises US$10m in a Series A financing led by YZR Capital and Relyens en France Innovation Santé with participation from Beiersdorf Venture Capital, Groupe Prunay, and existing investors. Jonathan Baptista Jean-Baptiste MORLOT Read more: https://lnkd.in/ewt9vtMP

French startup aims to accelerate drug discovery via ‘digital twins’ of cells DeepLife secures $10m to advance AI platform designed to identify molecular triggers capable of driving diseased cells into a healthy state. Jonathan Baptista Jean-Baptiste MORLOT #biotech #investment #AI #drugdiscovery

🎄✨ Season’s Greetings from the DeepLife Team! ✨🎄 As 2024 comes to a close, we’d like to extend our warmest wishes for a joyful and restful holiday season to all our colleagues, partners, and friends in the drug development community. This time of year is about recharging, connecting with loved ones, and maybe indulging in a few extra helpings of holiday treats. 🍪🎁 Come January, we’ll be back – possibly with a couple of extra pounds – but certainly with renewed energy and unstoppable motivation to continue driving innovation and accelerating drug development. Thank you for being part of our journey. Here’s to a brighter, healthier 2025 filled with breakthroughs and progress for patients everywhere! Happy Holidays, The DeepLife Team

🚀 Exciting news! We’re thrilled to announce that Beiersdorf CVC has invested in DeepLife, a techbio company leveraging GenAI to transform drug discovery. 🚀   🧬 DeepLife’s platform integrates cutting-edge digital twin technology, one of the world’s largest harmonized single-cell datasets, and advanced GenAI foundational models to accelerate target identification, drug repurposing, and toxicity assessments with unmatched efficiency and precision.   💰 This $10m Series A funding will support DeepLife’s ambitious plans to expand into the US, tapping into the world’s largest drug discovery market.   We’re excited to welcome the founders, Jonathan and Jean-Baptiste, to our portfolio and look forward to supporting their vision as they push the boundaries of bringing GenAI to life sciences.   Big shoutout to our co-investors YZR Capital (Markus, Paul), Turenne Groupe (Claire) and our CVC team — Ascan, Gunes, Chunchun, Christopher, Florian, and Anna, — for bringing this investment to life. The link to the full announcement by Sifted is in the comments! #Techbio #GenAI #LifeSciences #VentureCapital #Beiersdorf

Welcome to the YZR family DeepLife! 🧬 YZR led the $10m Series A round together with Turenne Groupe and joined by Beiersdorf, Groupe Prunay and the existing investors. DeepLife is a groundbreaking techbio company leveraging a proprietary database to provide digital twins of cells to household names in the pharma, biotech and adjacent industries. Its revolutionary approach for drug discovery increases speed and precision in testing novel drug combinations, particularly for diseases once deemed untreatable. We are excited to join the company on its mission to accelerate drug discovery and to further expand their footprint from France across Europe and beyond. A huge congratulations to Jonathan Baptista, Jean-Baptiste MORLOT and the whole team on this great success! You can find the link to the Sifted Article in the first comment. 👇 #Healthtech #Techbio #Venturecapital

Since Jonathan and Jean-Baptiste met at Entrepreneur First, they've been on a mission to transform drug discovery leveraging cutting-edge AI. Now, DeepLife is raising a $10 million Series A round and is expanding to the US, where they'll continue to develop their AI-powered models of biological systems to help pharma companies repurpose old drugs and find new treatment options faster. Excited to see what's next for this ambitious team!

DeepLife lève une série A de 10 millions de dollars pour poursuivre le développement de sa plateforme de jumeaux numériques de cellules alimentée par l'IA! Félicitations Jonathan Baptista, Jean-Baptiste MORLOT et toute l'équipe ! Nous sommes ravis de vous avoir accompagnés sur cette opération avec Sophie Gilbert et Grégoire Meynial (Sekri Valentin Zerrouk).